We are pleased to share the 2019 Patient Registry Annual Data Report with you during this exciting and yet sobering time. The exciting news is the rapid uptake of the triplecombination (elexacaftor/tezacaftor/ivacaftor) CFTR modulator. We are already seeing what appears to be a significant impact on the number of pulmonary exacerbations. Much more to follow in subsequent reports. While we are excited about the availability of this new therapy, we continue to invest in the Path to a Cure for everyone with cystic fibrosis.The sobering event that unfolded as we prepared this report is the COVID-19 pandemic. While the CF Foundation has partnered with the CF community to try to keep everyone safe including the provision of portable spirometers to facilitate telehealth visits, the patient registry team has played a pivotal role in a global effort to assess the impact of COVID-19 on people with CF. While people with CF do better than initially feared, it is clearly not a benign infection for those with CF, particularly for those with advanced lung disease and who have undergone transplantation. We continue to collect data on COVID-19 infections in the patient registry and collaborate with international colleagues to gather enough cases for a meaningful assessment of the short and long-term consequences of the infection on people with CF.Many thanks to each and every one of you who contribute to the success of the Registrymost importantly, people with CF and their families who generously agree to share their data and the Registry coordinators and care team members who collect and enter the data. It would not be possible without your vital contributions.